Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • ALS Association

    - PMLiVE

    Sandoz to acquire Just-Evotec Biologics to strengthen biosimilar development and manufacturing capabilities

    Acquisition will add in-house continuous manufacturing expertise and expand Sandoz’s biosimilar production capacity

    Biogen Idec building

    Biogen’s Qalsody granted MHRA approval to treat rare form of motor neurone disease

    Mutations in the SOD1 gene are responsible for approximately 2% of all cases of the disease

    - PMLiVE

    Eli Lilly and Alchemab Therapeutics enter ALS agreement worth up to $415m

    The deal follows the companies’ earlier partnership to advance candidates for the neurodegenerative disease

    - PMLiVE

    Eli Lilly and Alchemab Therapeutics partner to develop new ALS therapies

    The neurodegenerative disease affects approximately 30,000 people in the US

    - PMLiVE

    Innovate UK awards Sano Genetics £330,000 grant for ALS study

    The project will chart the psychological impacts of having a genetic predisposition to ALS

    Biogen Idec building

    Biogen’s Qalsody granted FDA accelerated approval for rare form of ALS

    Mutations in the SOD1 gene are responsible for approximately 2% of all cases

    - PMLiVE

    Cytokinetics to discontinue ALS drug candidate following phase 3 trial failure

    The neurodegenerative disease affects approximately 27,000 people in the US

    - PMLiVE

    Biogen’s tofersen shows promise in rare form of ALS in new data analysis

    Mutations in the SOD1 gene are responsible for approximately 2% of global ALS cases

    Cannes Lion 2022

    Our Top 5 Pharma Picks From Cannes Lions

    Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022.

    The Good Ideas Group

    - PMLiVE

    Almirall and Evotec team up in multi-target dermatology alliance

    The companies will focus on developing novel therapies for chronic skin diseases and skin cancer

    Biogen Idec building

    Biogen’s ALS drug tofersen misses phase 3 endpoint

    Following these results, Biogen will now expand its early access programme for tofersen to enable all eligible SOD1-ALS patients worldwide to receive the drug free of charge

    Open-Data Platforms for Direct Engagement with Patients, Researchers, and Pharma

    Indu Navar, CEO and Founder of EverythingALS, explores the roles of Artificial Intelligence, Machine Learning, and Brain Computer Interface in the search for a cure for ALS. She will also...

    Impetus Digital

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links